The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

New research reveals that sunburn may be caused by RNA damage, not DNA, challenging long-held beliefs about UV exposure ...

President Trump's $500 billion Stargate Initiative to build AI infrastructure faces blowback from his conspiracist supporters ...

We recently published a list of These 10 Firms Were Thursday’s Top Performers. In this article, we are going to take a look ...

Vaxxas and CEPI advance US$ 4.8 million programme for needle-free thermostable mRNA vaccines: Cambridge, Massachusetts Friday, January 24, 2025, 14:00 Hrs [IST] Vaxxas, a clinical ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

Traditional vaccines typically focus on the most accessible parts of viruses, which are often the rapidly mutating ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

The press release also contained forward-looking statements, cautioning that these are not guarantees and are subject to risks, uncertainties, and other factors that could cause actual results to ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...